Alopecia Areata
Conditions
Interventions
Experimental group:Yufa Microneedling in Combination with Halometasone
Control group:Halometasone
Sponsors
the First Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.an age range of 18 to 65 years, regardless of gender. 2.meet the clinical diagnostic criteria for baldness and have a severity grading of S1, S2 (scalp hair loss area of 0% to 50%). 3.no visual evidence of new hair regrowth within the past 3 months. 4.subjects are compliant, participate voluntarily and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. hair loss due to non-alopecia areata causes: androgenetic alopecia, syphilitic alopecia, resting alopecia, scarring alopecia, plucking fetish, ringworm and other causes of hair loss that may be due to genetic factors, endocrine disorders (e.g. thyroid disorders), connective tissue diseases (e.g. scleroderma, lupus erythematosus), infections or drugs. 2. patients with active inflammatory conditions such as erythema, flaking and papules on the scalp. 3. have received topical treatment for alopecia areata within the last 4 weeks: topical glucocorticoids, glucocorticoid encapsulation therapy, minoxidil, tacrolimus, prostaglandins, herbal preparations, topical immunotherapy, laser, cryotherapy, ultraviolet radiation, surgery and microneedling. 4. Systemic treatment for alopecia areata within the last 4 weeks: systemic glucocorticoids, cyclosporine, methotrexate, azathioprine, glycopyrrolate tablets, antihistamines, JAK inhibitors, traditional Chinese medicine and proprietary Chinese medicines. 5. Patients who are unable to undergo microneedling treatment such as those with severe combined chronic or uncontrolled acute diseases or psychiatric disorders. 6. those who have participated in any clinical trial within three months 7. Subjects who, in the judgment of the investigator, have conditions that, in the opinion of the investigator, make participation in this study inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of hair regrowth;SALT 50;SALT 75; | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean SALT change before and after treatment;Subjects' self-assessment;Adverse event occurrence rate; | — |
Countries
China
Contacts
Public ContactGuoqiang ZHANG
the First Hospital of Hebei Medical University
Outcome results
None listed